CANF
Can-Fite BioPharma Ltd.
$2.84
-0.35%
$6.1M
No data for this timeframe.
Vol
Market Cap$6.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders8 funds
Inst. Value$188.6K
Reddit Sentiment60° Warm
SEC Reports10
Press Releases4
Recent Activity
Jun 5, 2026
SEC
Can-Fite BioPharma's 2026 Annual General Meeting of Shareholders was adjourned due to lack of quorum and rescheduled for
6-K — Impact 2/10
Jun 4, 2026
SEC
Can-Fite BioPharma reported that its Annual General Meeting of Shareholders held on June 4, 2026, approved all five prop
6-K — Impact 2/10
Jun 4, 2026
Insider
Fishman Pnina was granted 24,000 shares
Chief Scientific Officer
Jun 4, 2026
Insider
Farbstein Motti was granted 24,000 shares
CEO, CFO and COO
Jun 2, 2026
SEC
Can-Fite BioPharma issued a press release highlighting positive clinical observations from its Phase 2a pancreatic cance
6-K — Impact 4/10
May 18, 2026
other
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
<p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globe
Mar 30, 2026
Press
Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 trial of Piclid
Impact 7/10
Mar 26, 2026
Press
Can-Fite BioPharma reported its 2025 financial results, showing a 40% year-over-year decline in revenue to $0.41 million
Impact 6/10
Price Targets
$5.00
+76.1% upside
Strong Buy
Current $2.84
Low $5.00
Median $5.00
High $5.00
1 analysts
$5.00
$5.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | D. Boral Capital | UPGRADE | Hold → Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 24, 2025 | D. Boral Capital | DOWNGRADE | Buy → Hold |
| Dec 17, 2025 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-1.04 | $-1.04 — $-1.04 | 1 | |
| Next FY | $-0.26 | $-0.26 — $-0.26 | 75% YoY | 1 |
Latest Reports
NEUTRAL
6-K
2/10
Can-Fite BioPharma's 2026 Annual General Meeting of Shareholders was adjourned due to lack of quorum and rescheduled for
Jun 5, 2026
NEUTRAL
6-K
2/10
Can-Fite BioPharma reported that its Annual General Meeting of Shareholders held on June 4, 2026, approved all five prop
Jun 4, 2026
BULLISH
Press
7/10
Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 trial of Piclid
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $105.9K | — |
| RHUMBLINE ADVISERS | $64.8K | — |
| CITIGROUP INC | $17.0K | — |
| FIFTH THIRD BANCORP | $465.00 | — |
| WELLS FARGO & COMPANY/MN | $388.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Fishman Pnina | A | $0.00 |
| Jun 4, 2026 | Farbstein Motti | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $188.6K total value (80,200 shares) as of 2026-Q1. Top holders: CITADEL, RHUMBLINE, CITIGROUP.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 34,150 | $105.9K | 56.1% | — |
| 2 | RHUMBLINE ADVISERS | 20,908 | $64.8K | 34.4% | — |
| 3 | CITIGROUP INC | 5,482 | $17.0K | 9.0% | — |
| 4 | FIFTH THIRD BANCORP | 150 | $465.00 | 0.2% | — |
| 5 | WELLS FARGO & COMPANY/MN | 125 | $388.00 | 0.2% | — |
| 6 | HRT FINANCIAL LP | 19,383 | $60.00 | 0.0% | — |
| 7 | TD Waterhouse Canada Inc. | 1 | $3.00 | 0.0% | — |
| 8 | MORGAN STANLEY | 1 | $3.00 | 0.0% | — |
2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Fishman Pnina | Chief Scientific Officer | AWARD | 24,000 | — | — |
| Jun 4, 2026 | Farbstein Motti | CEO, CFO and COO | AWARD | 24,000 | — | — |
10 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 7 neutral. Avg impact: 4.0/10.
NEUTRAL
6-K
2/10
Can-Fite BioPharma's 2026 Annual General Meeting of Shareholders was adjourned due to lack of quorum
Jun 5, 2026
NEUTRAL
6-K
2/10
Can-Fite BioPharma reported that its Annual General Meeting of Shareholders held on June 4, 2026, ap
Jun 4, 2026
NEUTRAL
6-K
4/10
Can-Fite BioPharma issued a press release highlighting positive clinical observations from its Phase
Jun 2, 2026
NEUTRAL
6-K
4/10
Can-Fite announced plans to advance its pancreatic cancer drug Namodenoson into a Phase 2b combinati
May 13, 2026
BULLISH
6-K
6/10
Can-Fite reported positive Phase 2a data for namodenoson in advanced pancreatic cancer, showing >30%
Apr 30, 2026
NEUTRAL
6-K
3/10
Can-Fite BioPharma is holding its 2026 Annual General Meeting of Shareholders, where shareholders wi
Apr 23, 2026
NEUTRAL
EFFECT
3/10
Can-Fite BioPharma's Form F-3 shelf registration (File No. 333-294760) became effective on April 3,
Apr 6, 2026
NEUTRAL
EFFECT
3/10
Can-Fite BioPharma has two shelf registration statements (File Nos. 333-269485 and 333-288890) that
Apr 1, 2026
BULLISH
6-K
7/10
Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Pha
Mar 30, 2026
MIXED
6-K
6/10
Can-Fite BioPharma reported its 2025 financial results, showing a 40% decline in revenue to $0.41 mi
Mar 26, 2026
BULLISH
7/10
Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Pha
Mar 30, 2026
MIXED
6/10
Can-Fite BioPharma reported its 2025 financial results, showing a 40% year-over-year decline in reve
Mar 26, 2026
NEUTRAL
5/10
Can-Fite BioPharma is facilitating the immediate cash exercise of existing warrants to purchase 795,
Mar 4, 2026
MIXED
6/10
Can-Fite BioPharma announced positive safety results from its Phase IIa trial of namodenoson in adva
Mar 4, 2026
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.00 mean target
+76.1% upside
Strong Buy (3.00)
$5.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $2.84 |
| Target Low | $5.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $5.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$-1.04 | $-1.04 | $-1.04 | — | — | — | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-0.26 | $-0.26 | $-0.26 | 75.0% | — | — | $0.0B | 0.0% | 1 |
2 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | D. Boral Capital | UPGRADE | Hold | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 24, 2025 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Dec 17, 2025 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
other
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
<p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4
May 5, 2026
short_interest
FTD: CANF — 216,615 shares ($0.7M) failed to deliver
Settlement: 20260505, Price: $3.32, FTD Value: $719,161.8, CAN-FITE BIOPHARMA LTD SPONSOR
May 4, 2026
short_interest
FTD: CANF — 333,865 shares ($1.0M) failed to deliver
Settlement: 20260504, Price: $2.93, FTD Value: $978,224.45, CAN-FITE BIOPHARMA LTD SPONSOR
May 1, 2026
short_interest
FTD: CANF — 408,655 shares ($1.3M) failed to deliver
Settlement: 20260501, Price: $3.19, FTD Value: $1,303,609.45, CAN-FITE BIOPHARMA LTD SPONSOR
Apr 30, 2026
other
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
<p align="justify"><i>Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.</i> (NYSE American: CANF) (TASE: CANF), a clini
Apr 30, 2026
short_volume
Short Volume: CANF — 56.3% short (6.1M / 10.9M)
Short: 6,112,875 | Exempt: 56,095 | TRF Vol: 10,858,494 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
announcement
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
<p align="center"><b>Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix</b></p>
Mar 26, 2026
earnings
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
<p align="left">RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jymT14PK5BWm5rCuVWEGZUCNtq
Mar 17, 2026
other
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
<p align="center"><i>Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market</i></p>
Mar 4, 2026
announcement
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
<p>RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”),
Mar 4, 2026
fda
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
<p><i>Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.</i> (NYSE American: CANF) (TASE: CANF), a clinical-stage biotech